Accelerated High-Dose tDCS for Depression: An Open-Label Outpatient Pilot Study

Date Added
October 7th, 2025
PRO Number
Pro00146983
Researcher
Mark George

List of Studies


Keywords
Depression, Nervous System
Summary

In this study, we are testing whether a higher dose of a non-invasive brain stimulation technique, called transcranial direct current stimulation (tDCS), can be safely used in people with depression. Participants will come to the Brain Stimulation Lab and receive mild electrical stimulation through electrodes placed on their scalp.

The study begins with a safety run-in, where the first few participants will receive stimulation at gradually increasing levels (2, 4, and 6 milliamps) while being closely monitored. If no serious side effects are found, later participants will receive repeated 6 milliamp sessions for 5 days total. We will check skin comfort, mood, and overall tolerability after each session.

Institution
MUSC
Recruitment Contact
Clayton Olash
843-243-7305
olash@musc.edu

A Prospective Multicenter Single-arm Clinical Study Investigating Clinical Outcomes when Cohealyx™ is used for the Management of Full Thickness Wounds Post-surgical Excision

Date Added
October 7th, 2025
PRO Number
Pro00146533
Researcher
Steven Kahn

List of Studies


Keywords
Surgery
Summary

This is a prospective single-arm post-market multicenter study to evaluate
clinical outcomes of Cohealyx when used to manage full thickness wounds
post-surgical excision. Patients with a full thickness wound where autografting is clinically indicated will be considered for participation in this study. Patients will
undergo a staged surgical procedure for wound closure. In the first surgery, Cohealyx will be applied to the surgically excised wound bed within 5-days post-injury. Once Cohealyx has successfully integrated into the wound bed, the wound will be prepped and autografted per standard of care.

Institution
MUSC
Recruitment Contact
Deanna DeHoff
843-792-8522
dehoff@musc.edu

Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors

Date Added
October 7th, 2025
PRO Number
Pro00146363
Researcher
Jason Newman

List of Studies

Keywords
Cancer
Summary

This study is for adult patients with head and neck cancer who are at risk of recurrence. The purpose of this study is to evaluate whether the use of Indocyanine Green (ICG) dye allows for better identification of tumor tissue during surgical procedures. Participation will include standard of care visits along with administration of ICG dye and imaging during surgery. Participation in this study will last approximately 6 weeks.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Fueling Strong Hearts for a Strong South Carolina

Date Added
October 5th, 2025
PRO Number
Pro00147696
Researcher
Ewan Williams

List of Studies

Keywords
Exercise, Nutrition, Stroke, Stroke Recovery
Summary

After leaving the hospital and finishing therapies, stroke survivors often do not have the supports they need to fully recover. Many live with problems for a long time after their stroke, such as trouble walking or doing everyday tasks like cleaning, grocery shopping, or cooking. Research suggests that healthy habits, like moving more, eating well, and being at a healthy weight, can improve most of these disabilities. These habits can be hard to form alone though, especially in rural areas that may not have many healthy foods or places to exercise. The goal of this research project is to test StrongPeople StrongHearts, a health program, to see if it helps stroke survivors in South Carolina make better choices for their health and improve their quality of life. The program will be delivered online so that survivors in rural areas can be in the program. One group will also receive a weekly grocery box tailored to their needs to improve access to healthy foods. This study could help increase access to research-based programs for stroke survivors who do not have the supports they did soon after their stroke.

Institution
MUSC
Recruitment Contact
Ewan Williams
843-792-3477
williaew@musc.edu

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)

Date Added
October 3rd, 2025
PRO Number
Pro00145467
Researcher
Anthony Dominick

List of Studies

Keywords
Cancer
Summary

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

Institution
MUSC
Recruitment Contact
Shanta Salzer
843-792-9300
salzers@musc.edu

Phase 2 Clinical Platform Trial Investigating Multiple Therapeutic Options for the Treatment of Hospitalized Patients with Acute Respiratory Distress Syndrome (ARDS)

Date Added
September 25th, 2025
PRO Number
Pro00146665
Researcher
Andrew Goodwin

List of Studies


Keywords
Critical Care
Summary

This is a Phase 2 platform research study that is assessing three different investigational medications (versus placebo) for hospitalized adults who have Acute Respiratory Distress Syndrome (ARDS). As a platform study, each of the three treatment groups will receive a different investigational drug (or placebo) depending on the severity of their ARDS. Participants will also receive standard treatment as determined by the treating physician.

Institution
MUSC
Recruitment Contact
Zerlinna Teague
(843) 792-0965
recruitment@musc.edu

A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Generalized Myasthenia Gravis

Date Added
September 22nd, 2025
PRO Number
Pro00147095
Researcher
Katherine Ruzhansky

List of Studies


Keywords
Autoimmune disease
Summary

The Propel study is for adults up to 75 years of age with Generalized Myasthenia Gravis (gMG) and looks at the efficacy of IMVT-1402 which is a once weekly subcutaneous investigational drug. The study contains a screening period, two blinded treatment periods, and a follow-up period. Treatment period one is 12 weeks, and participants will be randomized to 600 mg IMVT-1402, 300 mg IMVT-1402, or placebo during this time. Treatment period two is 14 weeks, and all participants will receive either 600 mg IMVT-1402 or 300 mg IMVT-1402 during this time. Total participation in the study will be about 35 weeks. Various medications used as standard of care for gMG will be allowed in this study, so participation does not necessarily require stopping current gMG treatment.

Institution
MUSC
Recruitment Contact
Emma McLeod
843-792-8008
mcleodem@musc.edu

Telerehabilitation in the home after stroke: A randomized, controlled, assessor-blinded clinical trial

Date Added
September 22nd, 2025
PRO Number
Pro00146909
Researcher
Parneet Grewal

List of Studies

Keywords
Stroke, Stroke Recovery
Summary

The purpose of this research study is to demonstrate that telerehabilitation targeting arm movement, when added to usual care, can improve arm function and reduce global disability after stroke, compared to usual care alone.

Telerehabilitation uses technology like video calls to provide therapy and medical support from a distance. This means patients can get care from their therapists without going to a clinic or hospital, making it easier for people, especially those with mobility issues or who live far away, to receive treatment

Institution
MUSC
Recruitment Contact
Parneet Grewal
8594475400
grewalp@musc.edu

A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)

Date Added
September 16th, 2025
PRO Number
Pro00146859
Researcher
Brian Lally

List of Studies

Keywords
Cancer, Drug Studies, Men's Health, Women's Health
Summary

The purpose of this study is to compare the usual treatment alone to the usual treatment plus dose escalated radiation. This study seeks to find if this approach is better or worse than standard of care for locally advanced pancreatic cancer. Treatment and follow up for this study may be up to 8 years. The procedures include CT or MRI scans, chemotherapy, and radiation therapy. Risks include stomach pain, diarrhea, nausea, vomiting, tiredness, muscle aches, and weight loss. You may or may not receive a direct benefit from participating in this trial, however, information learned from the trial may help other people in the future.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

BabySTrong (Stimulating the Tragus for Neural Growth): A Randomized Controlled Trial of taVNS-Paired Bottle Feeding to Improve Oral Feeding

Date Added
September 16th, 2025
PRO Number
Pro00146417
Researcher
Dorothea Jenkins

List of Studies


Keywords
Infant, Nerve
Summary

Preterm and term infants with brain injury frequently have difficulty learning to feed by mouth. Transcutaneous vagus nerve stimulation (taVNS) may be paired with the motor activity of feeding to boost brain circuits involved with feeding. This study will test a taVNS-paired bottle system in a blinded, randomized, controlled trial in infants who have reached term age and failed to learn to feed. Our preliminary data indicates that most infants improve their volume of oral feeds with the BabySTrong system, and 50-70% achieve full oral feeds and avoid placement of a gastrostomy tube (G-tube) or home nasogastric tube. The BabySTrong feeding system may improve oral feeding volumes and help infants and their families avoid a long hospital stay while trying to learn to feed.

Institution
MUSC
Recruitment Contact
Amy Boatright
843-792-2112
boatrigh@musc.edu



-- OR --